KAPVAY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for KAPVAY (KAPVAY).
Alpha-2 adrenergic receptor agonist; reduces sympathetic outflow from the CNS, decreasing peripheral vascular resistance and blood pressure.
| Metabolism | Hepatic (CYP2D6, CYP3A4); 50% first-pass metabolism. |
| Excretion | Renal: 40-60% unchanged; fecal: minimal (<10%); biliary: negligible. |
| Half-life | Terminal elimination half-life 12-16 hours (range 6-24 h) in adults; prolonged in renal impairment (up to 41 h) and in neonates. |
| Protein binding | 20-40%, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 2.1-3.0 L/kg; distributes extensively into tissues (e.g., CNS, kidneys). |
| Bioavailability | Transdermal: 60-70%; Oral immediate-release: 75-90%; Oral extended-release: 70-80% (relative to immediate-release). |
| Onset of Action | Transdermal: 2-3 days (due to slow skin absorption); Oral immediate-release: 30-60 min; Oral extended-release: 1-2 h; IV: 5-10 min. |
| Duration of Action | Transdermal: 7 days (single patch); Oral immediate-release: 6-8 h; Oral extended-release: 12-24 h; IV: 2-4 h. |
0.1 mg orally twice daily, may increase by 0.1 mg/day at weekly intervals; maximum 2.4 mg/day in divided doses.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | For GFR 10–50 mL/min: reduce dose by 25–50%; for GFR <10 mL/min: reduce dose by 50–75% and use with caution. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce starting dose by 50% and titrate cautiously; Child-Pugh C: avoid use or use with extreme caution. |
| Pediatric use | For hypertension (≥12 years): initial 0.1 mg orally twice daily; may titrate by 0.1 mg/day at weekly intervals; maximum 2.4 mg/day. For ADHD (6–17 years): 0.1–0.2 mg orally once daily at bedtime; titrate by 0.1 mg/day weekly; maximum 0.4 mg/day. |
| Geriatric use | Initiate at 0.1 mg orally once daily; monitor for hypotension and sedation; use lowest effective dose; avoid abrupt discontinuation. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for KAPVAY (KAPVAY).
| Breastfeeding | Clonidine is excreted into human milk. The milk-to-plasma (M/P) ratio is approximately 1.5 to 2.0. The relative infant dose is estimated to be 2-4% of the maternal weight-adjusted dose. However, because of potential serious adverse reactions in nursing infants, such as hypotension, bradycardia, or sedation, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Caution is advised. |
| Teratogenic Risk | Clonidine (KAPVAY) is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and increased fetal resorptions at high doses. There are no adequate and well-controlled studies in pregnant women. The drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Limited human data do not suggest a significantly increased risk of major birth defects. However, clonidine may cause maternal hypotension and decreased uteroplacental perfusion, potentially leading to fetal bradycardia, hypoxia, or growth restriction. In the third trimester, use may be associated with neonatal withdrawal symptoms (e.g., jitteriness, irritability, poor feeding, apnea) and/or maternal hypertension upon discontinuation. |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
["Hypersensitivity to clonidine","Severe bradyarrhythmia"]
| Precautions | ["Sedation","Withdrawal hypertension (rebound) with abrupt cessation","Bradycardia"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and signs of sedation. Assess fetal heart rate and uterine activity, especially when used for hypertensive disorders. In late pregnancy, monitor for signs of neonatal withdrawal or respiratory depression after delivery. Consider ultrasonography to assess fetal growth if long-term use. |
| Fertility Effects | Clonidine has been associated with decreased libido and impotence in males, and in females, it may disrupt ovulatory cycles due to alterations in gonadotropin secretion. Animal studies have shown reduced fertility at high doses. The clinical significance in humans is unclear but should be considered in patients planning conception. |